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Abstract
Importance—The long-term effectiveness of Helicobacter pylori eradication programs for
preventing gastric cancer will depend on recurrence risk and individual and community factors.
Objective—To estimate risk of H pylori recurrence and assess factors associated with successful
eradication 1 year after treatment.
Design, Setting, and Participants—Cohort analysis of 1463 randomized trial participants
aged 21 to 65 years from 7 Latin American communities, who were treated for H pylori and
observed between September 2009 and July 2011.
Interventions—Randomization to 1 of 3 treatment groups: 14-day lansoprazole, amoxicillin,
and clarithromycin (triple therapy); 5-day lansoprazole and amoxicillin followed by 5-day
lansoprazole, clarithromycin, and metronidazole (sequential); or 5-day lansoprazole, amoxicillin,
clarithromycin, and metronidazole (concomitant). Participants with a positive (13) C-urea breath
test (UBT) 6 to 8 weeks posttreatment were offered voluntary re-treatment with 14-day bismuth-
based quadruple therapy.
Measurements—Recurrent infection after a negative posttreatment UBT and factors associated
with successful eradication at 1-year follow-up.
Results—Among participants with UBT-negative results who had a 1-year follow-up UBT
(n=1091), 125 tested UBT positive, a recurrence risk of 11.5% (95% CI, 9.6%–13.5%).
Recurrence was significantly associated with study site (P=.03), nonadherence to initial therapy
(adjusted odds ratio [AOR], 2.94; 95% CI, 1.31–6.13; P=.01), and children in the household
(AOR, 1.17; 95% CI, 1.01–1.35 per child; P=.03). Of the 281 with positive posttreatment UBT
results, 138 completed re-treatment, of whom 93 tested UBT negative at 1 year. Among the 1340
who had a 1-year UBT, 80.4% (95% CI, 76.4%–83.9%), 79.8% (95% CI, 75.8%–83.5%), and
77.8% (95% CI, 73.6%–81.6%) had UBT-negative results in the triple, sequential, and
concomitant groups, respectively (P=.61), with 79.3% overall effectiveness (95% CI, 77.1%–
81.5%). In a single-treatment course analysis that ignored the effects of re-treatment, the
percentage of UBT-negative results at 1 year was 72.4% (95% CI, 69.9%–74.8%) and was
significantly associated with study site (P<.001), adherence to initial therapy (AOR, 0.26; 95% CI,
0.15–0.42; P<.001), male sex (AOR, 1.63; 95% CI, 1.25–2.13; P<.001), and age (AOR, 1.14; 95%
CI, 1.02–1.27 per decade; P=.02). One-year effectiveness among all 1463 enrolled participants,
considering all missing UBT results as positive, was 72.7% (95% CI, 70.3%–74.9%).
Conclusions and Relevance—One year after treatment for H pylori infection, recurrence
occurred in 11.5% of participants who had negative posttreatment UBT results. Recurrence
determinants (ie, nonadherence and demographics) may be as important as specific antibiotic
regimen in determining the long-term success of H pylori eradication interventions. Study findings
are relevant to the feasibility of programs for the primary prevention of gastric cancer in high-
incidence regions of Latin America.
Trial Registration—clinicaltrials.gov Identifier: NCT01061437
Gastric adenocarcinoma is the second leading cause of cancer death worldwide.1 Although
gastric cancer rates are declining in some areas, the number of deaths is expected to increase
over the coming decades due to growing and aging populations in high-incidence regions
such as Latin America and eastern Asia.2 Helicobacter pylori infects more than half of the
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world’s adult population, and chronic infection with this bacterium is the dominant risk
factor for gastric cancer, accounting for an estimated two-thirds of all cases globally.3,4
In a randomized trial in Shandong, China, eradication of H pylori using amoxicillin and
omeprazole reduced gastric cancer incidence by 39% over a 15-year period.5 If results of
this and other trials are confirmed,6–9 focused community eradication programs may offer a
promising approach for diminishing the enormous human and economic consequences of
this cancer. The feasibility of large-scale programs is uncertain and success in specific
populations will depend on the efficacy of the antibiotic regimen used and the risk of
recurrent infection following eradication.10,11
We observed a cohort of patients enrolled in a randomized trial in 7 community populations
in Latin America with moderate to high risk for gastric cancer to compare the short-term
effectiveness of 3 regimens in eradicating H pylori.12,13 We previously reported the results
of eradication therapy 6 to 8 weeks following randomization.14 One year after therapy, study
participants were retested to determine risk of recurrent infection and to assess factors that
influenced eradication effectiveness. We now present the key results of the 1-year follow-
up.
METHODS
The trial sites and methods have been previously reported14 and were coordinated by
SWOG, a federally funded cancer research cooperative group. In brief, men and women
aged 21 to 65 years were recruited and screened for eligibility in 7 Latin American
communities between September 2009 and June 2010. Potential participants were selected
using a census of households (Colombia, Costa Rica, Nicaragua), a large public clinic
registry (Chile), or household recruitment (Honduras and 2 sites in Mexico). Eligibility
requirements included having no prior treatment for H pylori infection and no significant
illness (eg, active cancer, other serious chronic illness).14 We explained the purpose and
eligibility requirements of the study to potential participants and those who expressed an
interest provided signed informed consent. The institutional review boards for each center
and the SWOG statistical center approved the study protocol.14
H pylori infection was assessed using the (13) C-urea breath test (UBT) with a 75-mg oral
dose of 13C-labeled urea, analyzed with infrared mass spectrometry (IRIS, Wagner
Analysen Technik). A change in 13C carbon dioxide, relative to a baseline of 4.0% or
greater, was considered positive. Serologic markers for the H pylori CagA protein
(cytotoxin-associated gene A) were assessed by IgG antibodies in the study laboratory in
Mexico (J.T.) by previously described methods.15 Standard instruments were used
(including the Rome III Diagnostic Questionnaire for the assessment of baseline dyspepsia
symptoms) to assess demographic factors, household conditions, and health history.16,17
Individuals who had positive UBT results and met other eligibility criteria were randomly
assigned by a central computer to 1 of 3 treatment groups using a web-based dynamic
randomization procedure that assured balance of sex, age, and study site across the 3
regimens. The treatments were: (1) triple therapy, given for 14 days of lansoprazole 30 mg,
amoxicillin 1000 mg, and clarithromycin 500 mg; (2) sequential therapy, given for 5 days of
lansoprazole 30 mg and amoxicillin 1000 mg, followed by 5 days of lansoprazole 30 mg,
clarithromycin 500 mg, and metronidazole 500 mg; and (3) concomitant therapy, given for 5
days of lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and
metronidazole 500 mg.18,19 All medications were taken twice per day. The medications
were generic and obtained from certified manufacturers. Treatment assignments were not
blinded.
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Participant follow-up was scheduled 6 to 8 weeks after randomization to include a UBT and
assessment of adverse effects and adherence (defined as having taken ≥80% of each drug of
the study regimen).14 Participants who had UBT-positive results at their follow-up visit
were offered a voluntary 14-day retreatment regimen of standard quadruple therapy with
twice-daily lansoprazole 30 mg, with tetracycline 500 mg, metronidazole 500 mg, and
bismuth subsalicylate 524 mg (or bismuth subcitrate 420 mg), each taken 4 times per
day.13,20 The protocol did not specify measures during re-treatment to encourage acceptance
or adherence, or to assess adverse effects or re-treatment effectiveness. The 1-year follow-up
examination, scheduled between 48 and 52 weeks following randomization for all
participants, included a UBT and final questionnaire.
Statistical Considerations
The trial sample size of 1470 participants was chosen to provide a greater than 80% power
to assess the first study aim—whether sequential therapy was superior to triple therapy and
whether concomitant therapy was noninferior to triple therapy in terms of eradication
success (UBT negativity) at the 6-to 8-week follow-up. This sample size was determined to
be sufficient to address the 1-year study goals of estimating recurrence risk and eradication
success. Specifically, we assumed a recurrence risk of as much as 10% based on prior
studies in Latin America,21,22 and with projected sample sizes of 1000 and 1400
participants, the estimated probabilities of recurrence and overall effectiveness would have
standard errors of 0.95% and 0.80%, respectively. Eradication success or failure was
determined by UBT results. The term infection recurrence was used to identify participants
who had UBT-negative results at the 6- to 8-week visit, but UBT-positive results at the 1-
year visit; H pylori strain data were not available for differentiating recrudescence (same
strain) and true reinfection (new strain).
Statistical analyses considered all participants as belonging to the treatment group to which
they were assigned, regardless of adherence to their assigned regimens. Analyses of
recurrence risk and treatment outcomes were based on participants who had a conclusive
(definite) UBT result at the 1-year visit. Treatment outcome results are also presented using
2 additional approaches: (1) a 1-year intent-to-treat analysis in which participants without a
follow-up UBT were considered as treatment failures (UBT positive); and (2) a single-
treatment course analysis in which the effects of retreatment were ignored, ie, participants
who had UBT-positive results at 6 to 8 weeks that became UBT negative at 1 year were
considered still to be UBT positive. A strategy of retesting all participants and re-treating
those with positive results shortly after initial eradication therapy may not be a cost-effective
cancer prevention strategy,23 and the single-treatment course analysis represents the 1-year
outcome of a strategy without re-treatment.
The 95% CIs for estimates of recurrence risk and treatment success were calculated using
the binomial exact method, and P values for comparisons among the 3 treatment groups for
these outcomes were based on the likelihood ratio χ2 test for independence. Univariate and
multivariate logistic regression analyses were used to explore associations between
participant characteristics and recurrence risk, initial treatment success, and 1-year treatment
success. Multivariate models were adjusted for the effects of age, sex, and study center. P
values for the standard logistic regression models were based on the Wald χ2 test statistic
and were 2-sided without adjustment for multiplicity, and values less than .05 were
considered statistically significant. Analyses were conducted using SAS version 9.2 and R
version 2.12.
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We identified 1859 adults who agreed to participate, of whom 1844 were potentially eligible
with positive UBT results (Figure). Exclusions included 375 individuals (20.3%) because of
negative UBT results, 7 withdrew consent, and 8 were ineligible on subsequent interviews.
Six individuals with negative UBT results were incorrectly randomized due to data entry
error and immediately withdrawn, leaving 1463 participants randomized to receive 1 of the
3 antibiotic regimens.
Table 1 shows participants’ characteristics according to their treatment assignment and
follow-up status: 59% were women, 55% older than 40 years, 84% were H pylori CagA
positive, and 26% had chronic dyspepsia symptoms. Reported use of alcohol (8%, ≥1 drink/
week) and tobacco (16%, ≥1 cigarette/d) was relatively infrequent. We obtained a
conclusive UBT result at the posttreatment (6- to 8-week) visit from 1414 participants
(96.7%) and from 1340 (91.6%) at the 1-year follow-up visit.
Infection Recurrence
Of the 1133 participants who were UBT negative following initial treatment, 1091 had a 1-
year UBT result, of whom 125 had become UBT positive, a recurrence risk of 11.5% (95%
CI, 9.6%–13.5%). The recurrence risk ranged from 6.8% in Costa Rica to 18.1% in
Colombia. Recurrence at 1 year was significantly associated with study site (P =.03),
number of children in the household (odds ratio [OR], 1.17; (95% CI, 1.01–1.35 per child; P
= .03), and nonadherence to therapy (OR, 2.94; 95% CI, 1.31–6.13; P =.01), but not with
treatment assignment (P =.63) (Table 2).
1-Year Outcomes
In the primary analysis of treatment effectiveness based on the 1340 participants with
definitive 1-year UBT results, the estimated 1-year eradication success rate was 80.4% (95%
CI, 76.4%–83.9%) for triple therapy, 79.8% (95% CI, 75.8%–83.5%) for sequential therapy,
and 77.8% (73.6%–81.6%) for concomitant therapy (P =.61). Overall effectiveness was
79.3% (95% CI, 77.1%–81.5%; Table 3). Outcome of treatment effectiveness among study
sites ranged from a higher level (87%–90%) in Costa Rica and Honduras to a lower level
(71%–76%) in Colombia, Nicaragua, and in Obregón and Tapachula, Mexico. Women 21 to
44 years of age were significantly less likely to have eradication success at 1 year (72.3%;
95% CI, 68.0%–76.2%) when compared with women 45 to 65 years of age (82.8%; 95% CI,
78.2%–86.8%), and when compared with men who were both younger (82.1%; 95% CI,
77.3%–86.2%) and older (85.6%; 95% CI, 80.5%–89.9%).
Of participants with positive post-treatment UBT results, 244 of 281 returned for a 1-year
examination. Of those who returned, 198 (81%) had accepted a prescription for re-treatment
quadruple therapy but only 138 (57%) reported that they had completed the regimen; 37
(15%) refused re-treatment. The UBT result had become negative for 38% overall (93/244)
and also for 54% of those who reported completing re-treatment (74/138). Of the individuals
with UBT-positive results who declined retreatment, 4 of 46 had UBT-negative results at 1
year.
In a 1-year analysis that included all 1463 randomized participants, and that considered as
treatment failures (UBT positive) the 123 individuals (8.4%) without a UBT result,
treatment effectiveness estimates were 74.6% (95% CI, 70.5%–78.4%), 73.3% (95% CI,
69.1%–77.1%), and 70.1% (95% CI, 65.9%–74.2%) for the triple, sequential, and
concomitant treatment groups, respectively, or about 7% lower than those in the analysis
mentioned previously. (Table 3).
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To explore the possible outcomes of a program without the retest and retreatment
component at 6 to 8 weeks, we conducted the single-treatment course analysis that
considered as treatment failures the 93 participants whose negative 1-year UBT had been
preceded by a positive UBT result at 6 to 8 weeks. Results of this analysis showed an overall
effectiveness of 72.4% (95% CI, 69.9%–74.8%; Table 3). Voluntary re-treatment tended to
dilute differences in effectiveness among the treatment groups, and removing these effects
yielded estimates of 75.5% (95% CI, 71.3%–79.4%), 72.4% (95% CI, 68.0%–76.5%), and
69.2% (95% CI, 64.6%–73.4%) for the triple, sequential, and concomitant therapy groups,
respectively (P =.11).
Predictors of Treatment Success
In the logistic regression models of the posttreatment (6–8 weeks) and the 1-year (single-
treatment course) outcomes (Table 4), significant associations were observed with study site,
male sex, older age, and adherence to initial therapy. Having fewer children in the household
was associated with the 1-year outcomes but not with 6- to 8-week outcome, while treatment
assignment was significantly associated with 6- to 8-week outcome,14 but not with 1-year
outcome. Other factors such as cigarette smoking, alcohol use, water source, sanitation, and
baseline chronic dyspepsia were unrelated to outcome (eTable, available at http://
www.jama.com).
COMMENT
In our 1-year follow-up study from this randomized trial in 7 community populations in
Latin America, the risk of recurrent H pylori infection following apparently successful
eradication was 11.5%. Although triple therapy in our initial analyses had appeared to be
superior to sequential and concomitant therapies at 6 to 8 weeks, there were only modest and
nonsignificant differences in 1-year outcomes among the 3 treatment groups. Triple therapy
succeeded in eradicating H pylori infection in 84.4% of participants who had a UBT 6 to 8
weeks posttreatment14 but its observed efficacy at 1 year was 80.4%, and its success was
estimated to be 75.5% if the effects of re-treating participants whose initial treatment had
failed were ignored. Significant predictors of successful eradication of H pylori infection at
1 year were study site, male sex, older age, and adherence to initial therapy.
Recurrence of Infection
The 11.5% 1-year recurrence risk observed in our trial is consistent with prior reports from
Latin America and other low- and middle-income regions.21,24,25 In a review by Gisbert21
of more than 100 studies, the overall annual recurrence risk ranged from 3.4% (95% CI,
3.1%–3.7%) in high-income countries to 8.7% (95% CI, 8.8%–9.6%) in lower-income
countries. In studies from Latin America with at least 50 person-years of follow-up,22,26–29
the 1-year recurrence risk ranged from 0% to 17.3%.28,29 In the largest prior study in Latin
America, conducted in Colombia, the mean annual recurrence rate over 6 years of cohort
follow-up was 5.4%.22 In our trial, the Colombia site had the highest recurrence risk
(18.1%), and notably, the participants were recruited from the same region as in the
aforementioned study. A high rate of recurrent infection was also seen in the eradication trial
from Shandong,5 wherein UBT negativity in the group treated with amoxicillin-based
treatment declined from 74% at 1 year to 47% by the seventh year.30 Nonetheless,
participants randomized to eradication therapy in the Shandong trial had a statistically
significant 39% decrease in gastric cancer incidence over a 14.7-year period of follow-up.5
H pylori recurrence in the first year following eradication seems likely to represent a
mixture of recrudescent infection and reinfection, whereas reinfection dominates in
subsequent years and the overall annual risk of recurrence tends to diminish.22,24,26 We
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found an association between recurrence with both medication nonadherence and study site
(a possible marker of regional antibiotic resistance), suggesting that recrudescence was an
important component of 1-year recurrence in the populations in this study.31 The borderline
association between number of children in the household and recurrence suggests that an
element of reinfection also occurred during the first year, consistent with previous reports
wherein number of children was a risk factor for infection.32,33 Our finding that women who
were between 21 and 44 years old were less likely to have successful 1-year eradication is
also consistent with a risk of reinfection mediated through contact with young children.
Differences in generic medications were unlikely to explain site differences because
Honduras and Nicaragua used drugs from the same batch and manufacturer in Central
America, yet they had disparate 1-year outcomes. Continued cohort follow-up should
provide important insights.
Implications of 1-Year Outcomes
The observed 1-year outcomes of our study represent a mixture of the effects of initial
eradication therapy, retreatment, recurrence, and participant and community characteristics.
Although H pylori eradication programs may be cost effective, particularly in high-
incidence areas,34–36 retesting and re-treating individuals shortly after initial eradication
therapy may not be cost effective, especially when the probability of successful eradication
with initial therapy is relatively high and the efficacy of re-treatment is modest.21 To
simulate a program that did not include an early retest and retreatment stage, we conducted
the single-treatment course analysis, which ignored the effects of voluntary retreatment. Our
estimated 75.5% success rate for triple therapy in this analysis was not remarkably better
than that for the other 2 regimens tested and the success of all 3 regimens without
retreatment was comparable to what has been reported from prior eradication trials.5–7,10
Thus, while our data underscore the continued use of 14-day triple therapy in Latin America,
from a program perspective they also point to the possible acceptability of a lower-cost
regimen (eg, sequential therapy). Assessment of program effectiveness must also consider
potential adverse outcomes such as adverse effects of treatment, rare serious events,37 and
the potential contribution to community antimicrobial resistance.38 In low- and middle-
income nations, the incremental effects of an eradication program on resistance are difficult
to gauge given the prevalence of unsanitary conditions that facilitate spread of resistant
bacteria and the common practice of self-prescription with over-the-counter antibiotics.39
In our current study, adherence, study site, sex, and age were significantly associated with
the probability of a successful 1-year outcome. From the public health perspective, a “one
size fits all” intervention strategy may not be optimal. For example, the fact that age-specific
rates of gastric cancer incidence in women lag those of men by 10 to 15 years,1 coupled with
the higher risk of recurrent infection in younger women, suggests that an eradication
program could enroll men beginning at age 30 years but delay enrolling women until they
reach 40 or 50 years of age. In general, programs will be more effective if tailored to the
demographics and community ecology of their target populations.40
The feasibility and success of an H pylori eradication strategy for preventing gastric cancer
focused on specific populations in high-risk regions will depend on the cancer risk in the
target population, the prevalence of virulent H pylori strains, the probability of success of
initial treatment, the risk of recurrent infection, and the per-person program cost of screening
and eradication. Eradication programs seem likely to be cost effective if they prevent at least
10% of cancer deaths,41,42 a threshold that was exceeded in the Shangdong Intervention
Trial5 and in a trial from Japan that randomized patients with resected gastric cancer to
antibiotics or placebo and observed a statistically significant 64% decrease in risk of
metachronous cancers over 3 years of follow-up.9 A combined analysis of the effects of 5
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randomized trials of H pylori eradiation on gastric cancer incidence5 reported a pooled
relative risk of 0.58 (95% CI, 0.42–0.81).5
Study Strengths and Limitations
Our trial was designed as a public health intervention with a vision toward future programs
of H pylori eradication in high-risk areas of Latin America. The trial incorporated data from
7 heterogeneous community populations in 6 countries, noninvasive H pylori testing with
UBT, generic medications purchased locally, and standard antimicrobial regimens.
However, this public health approach had inherent limitations. Participants were recruited
from the community and the results may not be generalizable to symptomatic patients
requiring clinical evaluation. We also did not assess antibiotic resistance or gastric
histology. Additionally, re-treatment of UBT-positive participants was voluntary, and thus,
efficacy estimates with quadruple therapy are qualified.
CONCLUSIONS
In this large study in diverse community populations in Latin America, our results indicate
that geographic site, demographic factors, adherence to initial therapy, and infection
recurrence may be as important as the choice of antibiotic regimen in H pylori eradication
interventions. Ongoing research initiatives are needed, given the expected increase in the
gastric cancer burden in Latin America over the next 2 decades, evidence that H pylori
infection is the dominant risk factor, and evidence that eradication reduces gastric cancer
risk.
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